Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇬🇧GB · Life Sciences#1575K to 30K
- 🇯🇵JP · Life Sciences#9610K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
7.5K to 30K🎙 Weekly cadence·59 episodes·Last published 6d ago - Monthly Reach
Unique listeners across all episodes (30 days)
15K to 60K🇬🇧50%🇯🇵50% - Active Followers
Loyal subscribers who consistently listen
4.5K to 18K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
From one target to many: how high‑plex ddPCR is changing CGT from development to analytics
Jun 24, 2026
15m 25s
Beyond one and done: engineering durable, redosable cell‑based gene therapies
Jun 17, 2026
18m 34s
Precision by design: engineering site‑specific ADCs with machine learning
May 21, 2026
24m 28s
Crossing the ADC inflection points: what separates clinical success from failure
Feb 23, 2026
30m 06s
Formulation and delivery of RNA-based vaccines and therapeutics: addressing outstanding questions around safety and purity
Nov 6, 2025
24m 22s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/24/26 | From one target to many: how high‑plex ddPCR is changing CGT from development to analytics | Lauren Coyle, Editor, BioInsights, speaks with Christian Overgaard, Senior Field Application Scientist, Bio‑Rad Laboratories, about the technical and practical evolution of droplet digital PCR (ddPCR) and high‑plex multiplexing, covering assay design challenges, vector integration analysis, biodistribution studies, and the emerging role of digital PCR in cell and gene therapy characterization and clinical development. | 15m 25s | ||||||
| 6/17/26 | Beyond one and done: engineering durable, redosable cell‑based gene therapies | The one‑and‑done model has defined gene therapy for a generation. Chris Hopkins thinks it is time to move on. At ASGCT 2026, Abi Pinchbeck spoke with the Co‑founder and CEO of Glafabra Therapeutics on redoseable cell‑based gene therapy, a platform spanning Fabry, Pompe, and Gaucher diseases, and what durable, if not permanent, treatment could mean for patients. A podcast version of this discussion is also available. | 18m 34s | ||||||
| 5/21/26 | Precision by design: engineering site‑specific ADCs with machine learning | Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Weston Kightlinger, CEO, Ridge Bio, about the challenge of DAR heterogeneity and site specificity in ADC development, Ridge Bio’s ML‑driven enzyme and linker engineering platforms, and what site‑specific conjugation means for the future of ADCs as the field moves beyond oncology. | 24m 28s | ||||||
| 2/23/26 | Crossing the ADC inflection points: what separates clinical success from failure | Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic. | 30m 06s | ||||||
| 11/6/25 | Formulation and delivery of RNA-based vaccines and therapeutics: addressing outstanding questions around safety and purity | In this interview, Róisin McGuigan, Editor, Nucleic Acid Insights, and Jesse Erasmus, Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery, and the key ongoing obstacles facing viral and LNP-based delivery modalities. | 24m 22s | ||||||
| 10/27/25 | Advancing nucleic acid therapeutics with circular RNA | In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment. | 33m 47s | ||||||
| 10/1/25 | Exploring advances in bioconjugation: nanozymes, tissue tropism, and the future of responsive systems | Lauren Coyle (Commissioning Editor, Bioconjugation Insights) speaks to Vincent Rotello (Distinguished Professor of Chemistry, University of Massachusetts Amherst) about the advantages and limitations of different nanomaterial platforms, and emerging strategies such as tissue tropism and responsive nanozymes that could advance targeted therapeutic and diagnostic delivery. | 15m 29s | ||||||
| 8/27/25 | The promise of antibody-oligonucleotide conjugates for neurological diseases | Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases. | 21m 22s | ||||||
| 7/18/25 | From innovation to access: bridging gaps in scalability and cold chain precision logistics for advanced therapies | Jokūbas Leikauskas, Editor, BioInsights, speaks to Rohin Iyer, Senior Director, Global Cell and Gene Therapy Operations, Marken, about addressing the complex logistics of cell and gene therapies through global infrastructure, precision, and advanced technologies. They also discuss evolving cold chain needs, regulatory and geopolitical challenges, and the need for scalability. | 19m 49s | ||||||
| 3/27/25 | Enhancing mRNA results through strategic RNA design and quality control | In the last few years, mRNA has moved to the fore in the vaccine and cell and gene therapy fields, and as a result, its successful production for these downstream applications has never been more crucial. In this podcast episode, Róisin McGuigan, Editor, Nucleic Acid Insights, speaks to Ryan Lahr, Senior R&D Scientist, CELLSCRIPT, about design, production, and quality control of synthesized mRNA for translation in cells. | 12m 53s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/13/25 | For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications | Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations. | 19m 09s | ||||||
| 2/19/25 | Exploring challenges, opportunities and state-of-the-art tools in the lipid nanoparticle space | Róisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Ketaki Deshmukh, Senior Scientist, Novo Nordisk, about advanced characterization tools for LNPs, challenges in extrahepatic delivery, scalability issues, and the potential impact of AI and machine learning (ML) on future LNP development. | 15m 03s | ||||||
| 1/27/25 | Driving innovation in cell and gene therapy: the role of AI and robotics | Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks with OmniaBio Inc.’s Kenneth Harris, Chief Strategy Officer and Head of AI, Mitchel Sivilotti, President and CEO, and Anthony Rotunno, Senior Vice President and General Manager/Site Head, about the innovative advancements in cell and gene therapy, focusing on how AI, automation, and robotics are revolutionizing manufacturing processes by reducing costs, increasing production capacity, and ultimately, improving patient outcom... | 15m 38s | ||||||
| 12/6/24 | Spatial mapping: shaping the future of I-O diagnostics and treatment | Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Banafshé Larijani, Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spatial mapping technology designed to improve cancer diagnostics and personalize treatment planning. | 38m 44s | ||||||
| 12/5/24 | Pioneering quality control in biomanufacturing of cell and gene therapies | Lauren Coyle, Commissioning Editor, speaks with Dhruv Sareen, Executive Director at Cedars-Sinai Biomanufacturing Center, and Johnathan Rodriguez, Quality Control Manager at Cedars-Sinai Biomanufacturing Center, about the roles of in-process controls, method validation, risk management, and automation in biomanufacturing. They will highlight strategies to ensure product safety, consistency, and regulatory compliance for cell and gene therapy products. | 28m 08s | ||||||
| 9/6/24 | Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field | For the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike. David McCall, Senior Editor, BioInsights, speaks to Eric Faulkner, President and Chief Strategist, Passage Health Associates, about the chequered history of market access in the advanced therapies field, and what lessons can be taken forward to ensure a successful and sustai... | 25m 36s | ||||||
| 6/14/24 | Insights into advanced therapies in the context of evolving funding and M&A environments | David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies. | 22m 37s | ||||||
| 5/10/24 | Fit for function: developing potency assays reflective of the in vivo environment | Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving target. Here, Charlotte Barker, Editor, Cell & Gene Therapy Insights, speaks with Giorgio Zenere, CMC technical project lead in the Global QC Technology Innovation Team, Kite Pharma, and Dirk Windgassen, Director of Analytical Development, Miltenyi Bio... | 28m 20s | ||||||
| 4/4/24 | Gene therapy is having a monumental year: how can the industry keep up with supply? | Lauren Coyle, Commissioning Editor, Cell & Gene Therapy Insights, talks with Suman Subramanian, Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing. | 23m 36s | ||||||
| 3/18/24 | A deep dive in to generative AI applications in I-O | Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with André Freitas, Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about the intersection of generative AI and experimental cancer treatments, with a focus on clinical trials, regulatory considerations, and leveraging emerging technologies for a transformative impact in I-O. | 43m 52s | ||||||
| 3/12/24 | Developing novel radioimmunotherapy combinations for lung cancer treatment | Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks to Joe Chang, Clinical Thoracic Oncologist, MD Anderson Cancer Center, University of Texas, who discusses his team’s pioneering work in combining radiation therapy with immunotherapy for lung cancer treatment. He highlights the challenges and promises of optimizing radioimmunotherapy combinations, emphasizing the importance of personalized treatment approaches and collaboration across disciplines to improve patient outcomes. | 14m 57s | ||||||
| 3/11/24 | Focusing on the fundamentals: what do and don’t we know about mRNA delivery? | As excitement around the evolving field of mRNA continues to grow, there remain some fundamental questions to be answered. David McCall, Senior Editor, Nucleic Acid Insights, spoke with Monash University’s Colin Pouton, Professor of Pharmaceutical Biology and Angus Johnston, Associate Professor, ARC Future Fellow about the key limitations and unknowns of current mRNA delivery approaches, and critical areas for further research and innovation to propel the field forward. | 45m 24s | ||||||
| 3/1/24 | Navigating genomics and transcriptomics in the immuno-oncology space | Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, interviews Katie Campbell, Postdoctoral Fellow, Cancer Research Institute, about her current research on genomics, transcriptomics, and spatial profiling to address challenges in the I-O field. | 20m 23s | ||||||
| 2/27/24 | Avian influenza and the risk of pandemic | With the potential for avian influenza to transmit and spread amongst humans, an effective vaccine to increase pandemic preparedness is a global priority. Charlotte Barker, Editor, Vaccine Insights, speaks with Mathilde Richard, Principal Investigator & Associate Professor at Erasmus MC, about investigating antigenic evolution of avian influenza viruses, developing better vaccines, and the need for proactive measures to ensure global preparedness in the face of evolving influenza threats. | 23m 38s | ||||||
| 12/4/23 | Exploring the landscape of novel targets & pathways in immuno-oncology | Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets. | 17m 05s | ||||||
Showing 25 of 62
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.